Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.

Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J.

Cell Death Dis. 2019 Oct 10;10(10):769. doi: 10.1038/s41419-019-1997-z.

2.

Functional characterization of novel germline TP53 variants in Swedish families.

Kharaziha P, Ceder S, Axell O, Krall M, Fotouhi O, Böhm S, Lain S, Borg Å, Larsson C, Wiman KG, Tham E, Bajalica-Lagercrantz S.

Clin Genet. 2019 Sep;96(3):216-225. doi: 10.1111/cge.13564. Epub 2019 Jul 2.

PMID:
31081129
3.

p53 as a hub in cellular redox regulation and therapeutic target in cancer.

Eriksson SE, Ceder S, Bykov VJN, Wiman KG.

J Mol Cell Biol. 2019 Apr 1;11(4):330-341. doi: 10.1093/jmcb/mjz005.

PMID:
30892598
4.

Correction: WRAP53 Is Essential for Cajal Body Formation and for Targeting the Survival of Motor Neuron Complex to Cajal Bodies.

Mahmoudi S, Henriksson S, Weibrecht I, Smith S, Söderberg O, Strömblad S, Wiman KG, Farnebo M.

PLoS Biol. 2018 Sep 25;16(9):e3000030. doi: 10.1371/journal.pbio.3000030. eCollection 2018 Sep.

5.

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells.

Synnott NC, Madden SF, Bykov VJN, Crown J, Wiman KG, Duffy MJ.

Transl Oncol. 2018 Dec;11(6):1343-1349. doi: 10.1016/j.tranon.2018.08.009. Epub 2018 Sep 6.

6.

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246.

Haffo L, Lu J, Bykov VJN, Martin SS, Ren X, Coppo L, Wiman KG, Holmgren A.

Sci Rep. 2018 Aug 23;8(1):12671. doi: 10.1038/s41598-018-31048-7.

7.

Role of Thiol Reactivity for Targeting Mutant p53.

Zhang Q, Bergman J, Wiman KG, Bykov VJN.

Cell Chem Biol. 2018 Oct 18;25(10):1219-1230.e3. doi: 10.1016/j.chembiol.2018.06.013. Epub 2018 Jul 26.

8.

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277.

Zhang Q, Bykov VJN, Wiman KG, Zawacka-Pankau J.

Cell Death Dis. 2018 May 1;9(5):439. doi: 10.1038/s41419-018-0463-7. Erratum in: Cell Death Dis. 2019 Oct 10;10(10):769.

9.

Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Ren W, Ye X, Su H, Li W, Liu D, Pirmoradian M, Wang X, Zhang B, Zhang Q, Chen L, Nie M, Liu Y, Meng B, Huang H, Jiang W, Zeng Y, Li W, Wu K, Hou Y, Wiman KG, Li Z, Zhang H, Peng R, Zhu S, Pan-Hammarström Q.

Blood. 2018 Jun 14;131(24):2670-2681. doi: 10.1182/blood-2017-11-817601. Epub 2018 Mar 15. Erratum in: Blood. 2019 Feb 7;133(6):620.

10.

Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors.

Zhang M, Heldin A, Palomar-Siles M, Öhlin S, Bykov VJN, Wiman KG.

Front Oncol. 2018 Jan 4;7:323. doi: 10.3389/fonc.2017.00323. eCollection 2017.

11.

Targeting mutant p53 for efficient cancer therapy.

Bykov VJN, Eriksson SE, Bianchi J, Wiman KG.

Nat Rev Cancer. 2018 Feb;18(2):89-102. doi: 10.1038/nrc.2017.109. Epub 2017 Dec 15. Review.

PMID:
29242642
12.

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Bykov VJN, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG.

J Biol Chem. 2017 Dec 1;292(48):19607. doi: 10.1074/jbc.AAC117.000815. No abstract available.

13.

Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.

Cheteh EH, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L, Bykov VJ, Östman A, Wiman KG.

Cell Death Dis. 2017 Jun 1;8(6):e2848. doi: 10.1038/cddis.2017.225.

14.

Mutant p53 targeting by the low molecular weight compound STIMA-1.

Zache N, Lambert JMR, Rökaeus N, Shen J, Hainaut P, Bergman J, Wiman KG, Bykov VJN.

Mol Oncol. 2017 May;11(5):595. doi: 10.1002/1878-0261.12065. No abstract available.

15.

Introduction to Nobel Conference: 'The Cell Cycle and Cell Death in Disease'.

Wiman KG, Zhivotovsky B.

J Intern Med. 2017 May;281(5):418-421. doi: 10.1111/joim.12618. No abstract available.

16.

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arnér ES, Wiman KG.

Cell Death Dis. 2017 Apr 13;8(4):e2751. doi: 10.1038/cddis.2016.137. No abstract available.

17.

Understanding cell cycle and cell death regulation provides novel weapons against human diseases.

Wiman KG, Zhivotovsky B.

J Intern Med. 2017 May;281(5):483-495. doi: 10.1111/joim.12609. Epub 2017 Apr 4. Review.

18.

Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulation.

Liu DS, Duong CP, Haupt S, Montgomery KG, House CM, Azar WJ, Pearson HB, Fisher OM, Read M, Guerra GR, Haupt Y, Cullinane C, Wiman KG, Abrahmsen L, Phillips WA, Clemons NJ.

Nat Commun. 2017 Mar 28;8:14844. doi: 10.1038/ncomms14844.

19.

PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2.

Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG.

Oncogene. 2017 Jun 22;36(25):3650. doi: 10.1038/onc.2017.9. Epub 2017 Feb 13.

PMID:
28192401
20.

Wrap53, a Natural p53 Antisense Transcript Required for p53 Induction upon DNA Damage.

Mahmoudi S, Henriksson S, Corcoran M, Méndez-Vidal C, Wiman KG, Farnebo M.

Mol Cell. 2016 Dec 1;64(5):1009. doi: 10.1016/j.molcel.2016.11.027. No abstract available.

21.

PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2.

Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG.

Oncogene. 2016 Dec 15;35(50):6446. doi: 10.1038/onc.2016.210. Epub 2016 Jul 4. No abstract available. Retraction in: Oncogene. 2017 Jun 22;36(25):3650.

PMID:
27375019
22.

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.

Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N.

J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.

23.

cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response.

Madapura HS, Salamon D, Wiman KG, Lain S, Klein E, Nagy N.

Cell Cycle. 2016 May 2;15(9):1267-75. doi: 10.1080/15384101.2016.1160975.

24.

Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.

Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG.

Front Oncol. 2016 Feb 3;6:21. doi: 10.3389/fonc.2016.00021. eCollection 2016. Review.

25.

Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis.

Bersani C, Huss M, Giacomello S, Xu LD, Bianchi J, Eriksson S, Jerhammar F, Alexeyenko A, Vilborg A, Lundeberg J, Lui WO, Wiman KG.

Oncotarget. 2016 Jan 12;7(2):1895-911. doi: 10.18632/oncotarget.6557.

26.

APR-246 potently inhibits tumour growth and overcomes chemoresistance in preclinical models of oesophageal adenocarcinoma.

Liu DS, Read M, Cullinane C, Azar WJ, Fennell CM, Montgomery KG, Haupt S, Haupt Y, Wiman KG, Duong CP, Clemons NJ, Phillips WA.

Gut. 2015 Oct;64(10):1506-16. doi: 10.1136/gutjnl-2015-309770. Epub 2015 Jul 17.

PMID:
26187504
27.

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.

Mohell N, Alfredsson J, Fransson Å, Uustalu M, Byström S, Gullbo J, Hallberg A, Bykov VJ, Björklund U, Wiman KG.

Cell Death Dis. 2015 Jun 18;6:e1794. doi: 10.1038/cddis.2015.143.

28.

TP53: an oncogene in disguise.

Soussi T, Wiman KG.

Cell Death Differ. 2015 Aug;22(8):1239-49. doi: 10.1038/cdd.2015.53. Epub 2015 May 29. Review.

29.

Expression of the p53 target Wig-1 is associated with HPV status and patient survival in cervical carcinoma.

Xu LD, Muller S, Thoppe SR, Hellborg F, Kanter L, Lerner M, Zheng B, Lagercrantz SB, Grandér D, Wallin KL, Wiman KG, Larsson C, Andersson S.

PLoS One. 2014 Nov 7;9(11):e111125. doi: 10.1371/journal.pone.0111125. eCollection 2014.

30.

Mutant p53 reactivation by small molecules makes its way to the clinic.

Bykov VJ, Wiman KG.

FEBS Lett. 2014 Aug 19;588(16):2622-7. doi: 10.1016/j.febslet.2014.04.017. Epub 2014 Apr 24. Review.

31.

Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3σ.

Bersani C, Xu LD, Vilborg A, Lui WO, Wiman KG.

Oncogene. 2014 Aug 28;33(35):4407-17. doi: 10.1038/onc.2013.594. Epub 2014 Jan 27.

32.

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.

Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD, Lee EF, Lindstrom MS, Wiman KG, Huang DC, Bouillet P, Rowe M, Rickinson AB, Herold MJ, Strasser A.

Genes Dev. 2014 Jan 1;28(1):58-70. doi: 10.1101/gad.232009.113.

33.

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.

Peng X, Zhang MQ, Conserva F, Hosny G, Selivanova G, Bykov VJ, Arnér ES, Wiman KG.

Cell Death Dis. 2013 Oct 24;4:e881. doi: 10.1038/cddis.2013.417. Erratum in: Cell Death Dis. 2017 Apr 13;8(4):e2751.

34.

p53 talks to PARP: the increasing complexity of p53-induced cell death.

Wiman KG.

Cell Death Differ. 2013 Nov;20(11):1438-9. doi: 10.1038/cdd.2013.111. No abstract available.

35.

Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET.

Shalom-Feuerstein R, Serror L, Aberdam E, Müller FJ, van Bokhoven H, Wiman KG, Zhou H, Aberdam D, Petit I.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2152-6. doi: 10.1073/pnas.1201753109. Epub 2013 Jan 25.

36.

APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations.

Shen J, van den Bogaard EH, Kouwenhoven EN, Bykov VJ, Rinne T, Zhang Q, Tjabringa GS, Gilissen C, van Heeringen SJ, Schalkwijk J, van Bokhoven H, Wiman KG, Zhou H.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2157-62. doi: 10.1073/pnas.1201993110. Epub 2013 Jan 25.

37.

p53 contributes to T cell homeostasis through the induction of pro-apoptotic SAP.

Madapura HS, Salamon D, Wiman KG, Lain S, Klein G, Klein E, Nagy N.

Cell Cycle. 2012 Dec 15;11(24):4563-9. doi: 10.4161/cc.22810. Epub 2012 Nov 19.

38.

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, Paul C, Wiman KG, Andersson PO.

J Clin Oncol. 2012 Oct 10;30(29):3633-9. doi: 10.1200/JCO.2011.40.7783. Epub 2012 Sep 10.

PMID:
22965953
39.

Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth.

Vilborg A, Bersani C, Wickström M, Segerström L, Kogner P, Wiman KG.

Cell Death Dis. 2012 Apr 19;3:e298. doi: 10.1038/cddis.2012.33.

40.

The p53 target Wig-1: a regulator of mRNA stability and stem cell fate?

Vilborg A, Bersani C, Wilhelm MT, Wiman KG.

Cell Death Differ. 2011 Sep;18(9):1434-40. doi: 10.1038/cdd.2011.20. Epub 2011 Mar 11. Review.

41.

WRAP53 is essential for Cajal body formation and for targeting the survival of motor neuron complex to Cajal bodies.

Mahmoudi S, Henriksson S, Weibrecht I, Smith S, Söderberg O, Strömblad S, Wiman KG, Farnebo M.

PLoS Biol. 2010 Nov 2;8(11):e1000521. doi: 10.1371/journal.pbio.1000521. Erratum in: PLoS Biol. 2018 Sep 25;16(9):e3000030.

42.

PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.

Rökaeus N, Shen J, Eckhardt I, Bykov VJ, Wiman KG, Wilhelm MT.

Oncogene. 2010 Dec 9;29(49):6442-51. doi: 10.1038/onc.2010.382. Epub 2010 Sep 6.

PMID:
20818419
43.

Effects of the TP53 p.R249S mutant on proliferation and clonogenic properties in human hepatocellular carcinoma cell lines: interaction with hepatitis B virus X protein.

Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC, Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG, Hantz O, Caron de Fromentel C, Chemin IA, Hainaut PL.

Carcinogenesis. 2010 Aug;31(8):1475-82. doi: 10.1093/carcin/bgq118. Epub 2010 Jun 10.

PMID:
20538734
44.

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.

Wiman KG.

Oncogene. 2010 Jul 29;29(30):4245-52. doi: 10.1038/onc.2010.188. Epub 2010 May 24. Review.

PMID:
20498645
45.

The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.

Farnebo M, Bykov VJ, Wiman KG.

Biochem Biophys Res Commun. 2010 May 21;396(1):85-9. doi: 10.1016/j.bbrc.2010.02.152. Review.

PMID:
20494116
46.

Extract from Asteraceae Brachylaena ramiflora induces apoptosis preferentially in mutant p53-expressing human tumor cells.

Karimi M, Conserva F, Mahmoudi S, Bergman J, Wiman KG, Bykov VJ.

Carcinogenesis. 2010 Jun;31(6):1045-53. doi: 10.1093/carcin/bgq084. Epub 2010 Apr 28.

PMID:
20427345
47.

Regulation of tumor suppressor p53 at the RNA level.

Vilborg A, Wilhelm MT, Wiman KG.

J Mol Med (Berl). 2010 Jul;88(7):645-52. doi: 10.1007/s00109-010-0609-2. Epub 2010 Mar 21. Review.

PMID:
20306257
48.

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis.

Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ.

Oncogene. 2010 Mar 4;29(9):1329-38. doi: 10.1038/onc.2009.425. Epub 2009 Nov 30.

PMID:
19946333
49.

The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element.

Vilborg A, Glahder JA, Wilhelm MT, Bersani C, Corcoran M, Mahmoudi S, Rosenstierne M, Grandér D, Farnebo M, Norrild B, Wiman KG.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15756-61. doi: 10.1073/pnas.0900862106. Epub 2009 Sep 1.

50.

30 years and a long way into p53 research.

Hainaut P, Wiman KG.

Lancet Oncol. 2009 Sep;10(9):913-9. doi: 10.1016/S1470-2045(09)70198-6.

PMID:
19717093

Supplemental Content

Loading ...
Support Center